Levosimendan in patients with mechanical circulatory support

Česká verzia

Authors: MUDr. Hynek Říha, Ph.D.; Fccp ^1,2; MUDr. Petr Syrovátka; Ph.D. ¹; MUDr. Petr Kramář ¹; MUDr. Marian Pinďák ¹; MUDr. Leona Říhová ¹; MUDr. Zdeněk Matloch ¹; MUDr. Ivan Netuka; Ph.D. ³; MUDr. Tomáš Kotulák ^1,2
Authors place of work: Klinika anesteziologie a resuscitace Kardiocentrum IKEM, Praha ¹; Klinika anesteziologie, resuscitace a intenzivní medicíny, 1. LF UK, Praha ²; Klinika kardiovaskulární chirurgie Kardiocentrum IKEM, Praha hynek. riha@ikem. cz ³
Published in the journal: Kardiol Rev Int Med 2013, 15(2): 104-106
Category:

Summary

Levosimendan, calcium- sensitizer, is the last addition to inotropes available in clinical practice. It belongs to the group of inodilators, i.e., it increases myocardial contractility and concurrently decreases vascular resistance in pulmonary and systemic vascular beds. Levosimendan has favourable pharmacokinetics with active metabolite. All of these positive properties and effects are used in the patients before, during and after the implantation of different types of mechanical circulatory support devices.

Keywords:
levosimendan – heart failure – mechanical circulatory support

Zdroje

1. Kivikko M, Antila S, Eha J et al. Pharmacodynamics and safety of a new calcium sensitizer, levosimendan, and its metabolites during an extended infusion in patients with severe heart failure. J Clin Pharmacol 2002; 42: 43– 51.

2. Sandell EP, Hayha M, Antila S et al. Pharmacokinetics of levosimendan in healthy volunteers and patients with congestive heart failure. J Cardiovasc Pharmacol 1995; 26 Suppl 1: S57– S62.

3. Kivikko M, Antila S, Eha J et al. Pharmacokinetics of levosimendan and its metabolites during and after a 24--hour continuous infusion in patients with severe heart failure. Int J Clin Pharmacol Ther 2002; 40: 465– 471.

4. Papp Z, Édes I, Fruhwald S et al. Levosimendan: Molecular mechanisms and clinical implications: consensus of experts on the mechanisms of action of levosimendan. Int J Cardiol 2012; 159: 82– 87.

5. Leppikangas H, Järvelä K, Sisto T et al. Preoperative levosimendan infusion in combined aortic valve and coronary bypass surgery. Br J Anaesth 2011; 106: 298– 304.

6. Brezina A, Riha H, Pirk J. Prophylactic application of levosimendan in cardiac surgical patients with severe left ventricle dysfunction. Exp Clin Cardiol 2009; 14: e31– e34.

7. Lomivorotov VV, Boboshko VA, Efremov SM et al. Levosimendan versus an intra- aortic balloon pump in high‑risk cardiac patients. J Cardiothorac Vasc Anesth 2012; 26: 596– 603.

8. Suominen PK. Single‑center experience with levosimendan in children undergoing cardiac surgery and in children with decompensated heart failure. BMC anesthesiology 2011; 11: 18.

9. Mebazaa A, Pitsis AA, Rudiger A et al. Clinical review: practical recommendations on the management of perioperative heart failure in cardiac surgery. Crit Care 2010; 14: 201.

10. Toller W, Algotsson L, Guarracino F et al. Perioperative use of levosimendan: best practice in operative settings. J Cardiothorac Vasc Anesth 2013; 27. [Epub ahead of print].

11. Levy JH, Tanaka KA. Inflammatory response to cardiopulmonary bypass. Ann Thorac Surg 2003; 75: S715– S720.

12. Riha H, Augoustides JG. Pro: methylene blue as a rescue therapy for vasoplegia after cardiac surgery. J Cardiothorac Vasc Anesth 2011; 25: 736– 738.

13. Augoustides JG, Riha H. Recent progress in heart failure treatment and heart transplantation. J Cardiothorac Vasc Anesth 2009; 23: 738– 748.

14. Malfatto G, Della Rosa F, Villani A et al. Intermittent levosimendan infusions in advanced heart failure: favourable effects on left ventricular function, neurohormonal balance, and one‑year survival. J Cardiovasc Pharmacol 2012; 60: 450– 455.

15. Říha H, Netuka I, Kotulák T et al. Dysfunkce pravé komory po implantaci levostranné mechanické srdeční podpory. Vnitř Lék 2010; 56: 30– 36.

16. Sponga S, Ivanitskaia E, Potapov E et al. Preoperative treatment with levosimendan in candidates for mechanical circulatory support. ASAIO J 2012; 58: 6– 11.

17. Říha H, Kotulák T, Netuka I et al. Intenzivní péče o pacienty po implantaci mechanických srdečních podpor. Cor Vasa 2011;53:94– 98.

18. Kettner J, Dorazilová Z, Netuka I et al. Is severe pulmonary hypertension a contraindication for orthotopic heart transplantation? Not any more. Physiol Res 2011; 60: 769– 775.

19. Netuka I, Malý J, Szárszoi O et al. Technika implantace a zkušenosti s dočasnou mechanickou srdeční podporou při selhání pravé komory. Rozhl Chir 2011; 90: 88– 94.

20. Riha H, Kotulak T, Syrovatka P et al. eComment: Hemodynamic monitoring with LiDCOplus system in the patients supported by isolated right ventricular assist device. Interact Cardiovasc Thorac Surg 2011; 13: 57.

21. Beiras- Fernandez A, Weis FC, Fuchs H et al. Levosimendan treatment after primary organ failure in heart transplantation: a direct way to recovery? Transplantation 2006; 82: 1101– 1103.

22. Beiras- Fernandez A, Weis FC, Kur F et al. Primary graft failure and Ca2+ sensitizers after heart transplantation. Transplant Proc 2008; 40: 951– 952.

23. Beiras-Fernandez A, Kur F, Kaczmarek I et al. Levosimendan for primary graft failure after heart transplantation: a 3‑year follow‑up. Transplant Proc 2011; 43: 2260– 2262.